Jose Juan Almagro Armenteros, Caroline Brorsson, Christian Holm Johansen, Karina Banasik, Gianluca Mazzoni, Robert Moulder, Karoliina Hirvonen, Tomi Suomi, Omid Rasool, Sylvaine F A Bruggraber, M Loredana Marcovecchio, Emile Hendricks, Naba Al-Sari, Ismo Mattila, Cristina Legido-Quigley, Tommi Suvitaival, Piotr J Chmura, Mikael Knip, Anke M Schulte, Jeong Heon Lee, Guido Sebastiani, Giuseppina Emanuela Grieco, Laura L Elo, Simranjeet Kaur, Flemming Pociot, Francesco Dotta, Tim Tree, Riitta Lahesmaa, Lut Overbergh, Chantal Mathieu, Mark Peakman, Søren Brunak
AIMS: Heterogeneity in the rate of β-cell loss in newly diagnosed type 1 diabetes patients is poorly understood and creates a barrier to designing and interpreting disease-modifying clinical trials. Integrative analyses of baseline multi-omics data obtained after the diagnosis of type 1 diabetes may provide mechanistic insight into the diverse rates of disease progression after type 1 diabetes diagnosis. METHODS: We collected samples in a pan-European consortium that enabled the concerted analysis of five different omics modalities in data from 97 newly diagnosed patients...
July 2024: Diabetes/metabolism Research and Reviews